Dominion Diagnostics Licenses Rights to LifeGen Genetic Test Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Dominion Diagnostics today said that it has licensed rights to genetic testing technology from LifeGen.

The firms are currently collaborating on a study to validate LifeGen's test, which determines a patient's Genetic Addiction Risk Score. The test is being compared in the study to the Addiction Severity Index marketed by Inflexxion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.